Overview
- The New England Journal of Medicine paper published Monday, May 25, 2026 reports that an experimental RNA‑based therapy called VERVE‑102 produced sustained, dose‑dependent LDL drops of more than 60% at the highest dose in the first 35 trial participants.
- VERVE‑102 uses a liver‑targeting lipid nanoparticle to deliver two short RNA fragments that find and inactivate the PCSK9 gene in hepatocytes so the liver stops making the PCSK9 protein that raises LDL levels.
- Safety data in these 35 patients showed no major adverse events judged attributable to the therapy, with about 20% experiencing mild, transient infusion reactions and one case of pneumonitis deemed unrelated; a separate earlier program, VERVE‑101, was halted after a serious event and regulators remain focused on safety.
- Eli Lilly acquired Verve Therapeutics in June 2025 and the FDA gave VERVE‑102 Fast Track status last year, but the multicenter phase 1/2 trial will continue through 2027 with about 85 planned participants and no formal phase‑2 start has been announced.
- If larger, longer trials confirm these findings the approach could reduce the need for lifelong daily pills or repeat injections by delivering a long‑lasting LDL lowering effect, though regulators require extended safety follow‑up and broader testing before clinical use.